Oasmia Pharmaceuticals AB Stock Quote OASM - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

1.55

Bid

1.01

Ask

2.14

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

833.967M

Previous Close

1.55

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

538,043,000

Dividend Yield

PE Ratio

-21.77

Earnings Per Share (EPS)

-0.24

Revenue

9.5M

Net Profit

-128.74M

Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company which develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. It focuses on the development of manufacturing activity of novel formulations based on cytostatic which shows improved pro... Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company which develops, manufactures, markets and sells a new generation of drugs within human and veterinary oncology. It focuses on the development of manufacturing activity of novel formulations based on cytostatic which shows improved properties, a reduced side-effect profile, and an expanded therapeutic area. The products and product candidates utilize a proprietary, nanoparticle formulation technology that is designed to facilitate the administration of intravenously-delivered active pharmaceutical ingredients, without the addition of toxic solvents. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.vivesto.com

Headquarters

Uppsala, Swe

Founded

CORRECTING and REPLACING Whiting and Oasis to Combine in $6.0 Billion Merger of Equals Transaction

Creating a Scaled Unconventional U.S. Oil Producer with a Premier Williston Basin Acreage Position Totaling 972K Net Acres and Combined 4Q21 Production of 167.8 Thousand Boepd Transaction...

Whiting and Oasis to Combine in $6.0 Billion Merger of Equals Transaction

Creating a Scaled Unconventional U.S. Oil Producer with a Premier Williston Basin Acreage Position Totaling 972K Net Acres and Combined 4Q21 Production of 167.8 Thousand Boepd Transaction...

New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted

Oasmia Pharmaceutical AB (Nasdaq: OASM) announces that the United States Patent and Trademark Office (USPTO) has issued a notification of allowance of a patent for its unique nanotech method to...

Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma

Overall response rate data from the (RXE) Phase II study conducted in the US and Sweden met its primary end points and treatment with Doxophos Vet was generally well tolerated. Oasmia’s...

Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European Union

Apealea receives positive CHMP opinion in the European Union for treatment of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer in combination with...

Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in Russia

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that it has received marketing approval of Doxophos in...

Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS markets

Oasmia Pharmaceutical AB (NASDAQ: OASM) has entered into a new exclusive marketing and distributions agreement with Hetero Group (Hetero) with the goal of driving revenue in Russia and other...

Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS markets

Oasmia Pharmaceutical AB (NASDAQ: OASM) has entered into a new exclusive marketing and distributions agreement with Hetero Group (Hetero) with the goal of driving revenue in Russia and other...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
RZLVRezolve AI Ltd	$ 7.7301 (57.12%)	2.89M
RNAZTransCode Therapeutics Inc	$ 0.6371 (52.82%)	8.96M
ATGLAlpha Technology Group Limited	$ 2.12 (46.95%)	3.06M
INVZWInnoviz Technologies Ltd	$ 0.18 (45.69%)	11.02k
OCTOEightco Holdings Inc	$ 3.6065 (44.84%)	98.88M
VTNRVertex Energy Inc	$ 0.1537 (-57.42%)	46.35M
CMCTCreative Media and Community Trust Corporation	$ 0.709 (-54.70%)	3.33M
SFIXStitch Fix Inc	$ 2.305 (-38.53%)	19.91M
SHOTWSafety Shot Inc	$ 0.22 (-31.25%)	11.25k
BNZIBanzai International Inc	$ 5.75 (-30.22%)	2.65M
NVDANVIDIA Corporation	$ 123.4217 (2.11%)	240.08M
MLGOMicroAlgo Inc	$ 0.2669 (23.45%)	130.87M
CEROCERo Therapeutics Holdings Inc	$ 0.1026 (9.50%)	118.18M
SQQQProShares UltraPro Short QQQ	$ 7.495 (-2.03%)	111.54M
OCTOEightco Holdings Inc	$ 3.6094 (44.96%)	98.88M